AstraZeneca's Tagrisso-Chemo Combo Under FDA Priority Review For Most Common Form ...

Retrieved on: 2023-10-16 20:23:03

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's Tagrisso-Chemo Combo Under FDA Priority Review For Most Common Form .... View article details on hiswai:

Excerpt

AstraZeneca Plc's (NASDAQ: AZN) supplemental New Drug Application for Tagrisso (osimertinib) in combination with chemotherapy has been accepted ...

Article found on: www.benzinga.com